| Literature DB >> 26576228 |
Szilárd Kun1, Gergő A Molnár1, Eszter Sélley1, Lívia Szélig2, Lajos Bogár2, Csaba Csontos2, Attila Miseta3, István Wittmann1.
Abstract
Hydroxyl radical converts Phe to para-, meta-, and ortho-Tyr (p-Tyr, m-Tyr, o-Tyr), while Phe is converted enzymatically to p-Tyr in the kidney and could serve as substrate for gluconeogenesis. Pathological isoforms m- and o-Tyr are supposed to be involved in development of hormone resistances. Role of Phe and the three Tyr isoforms in influencing insulin need was examined in 25 nondiabetic septic patients. Daily insulin dose (DID) and insulin-glucose product (IGP) were calculated. Serum and urinary levels of Phe and Tyr isoforms were determined using a rpHPLC-method. Urinary m-Tyr/p-Tyr ratio was higher in patients with DID and IGP over median compared to those below median (P = 0.005 and P = 0.01, resp.). Urinary m-Tyr and m-Tyr/p-Tyr ratio showed positive correlation with DID (P = 0.009 and P = 0.023, resp.) and with IGP (P = 0.004 and P = 0.008, resp.). Serum Phe was a negative predictor, while serum p-Tyr/Phe ratio was positive predictor of both DID and IGP. Urinary m-Tyr and urinary m-Tyr/p-Tyr, o-Tyr/p-Tyr, and (m-Tyr+o-Tyr)/p-Tyr ratios were positive predictors of both DID and IGP. Phe and Tyr isoforms have a predictive role in carbohydrate metabolism of nondiabetic septic patients. Phe may serve as substrate for renal gluconeogenesis via enzymatically produced p-Tyr, while hydroxyl radical derived Phe products may interfere with insulin action.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26576228 PMCID: PMC4630663 DOI: 10.1155/2015/839748
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Chromatograms of a standard (STD), a serum (SE), and a urine sample of a septic patient (U). p-Tyr, para-tyrosine; m-Tyr, meta-tyrosine; o-Tyr, ortho-tyrosine; Phe, phenylalanine.
Baseline demographics, clinical data, and amino acid parameters of patients.
|
| 25 |
| Age [years] | 69 ± 14 |
| Male/female | 14/11 |
| Body weight [kg] | 80 (13) |
| Source of sepsis | |
| Lung | 13 |
| Kidney | 2 |
| Burned skin | 7 |
| Wound | 1 |
| Abdomen | 2 |
| APACHE II | 16 (10) |
| MODS | 5 (5) |
| SAPS II | 37.5 (20) |
| Serum creatinine [ | 118 95.5 |
| hsCRP [mg/L] | 154.2 ± 92.8 |
| PCT [ng/mL] | 7.62 19.23 |
| Daily urine output [mL] | 2055 (1775) |
| Mean daily glucose [mmol/L] | 9.0 2.5 |
| DID [U/day] | 19 (25) |
| IGP [U∗mmol/L] | 183.4223 261.2992 |
| Number of patients receiving hydrocortisone | 18 (72%) |
| Daily hydrocortisone dose [mg/day] | 200 (100) |
| Number of patients receiving dobutamine | 10 (40%) |
| Daily dobutamine dose [mg/day] | 275.0 537.5 |
| Serum | 45.177 ± 18.049 |
| Serum | 14 (27) |
| Serum | 14 (15) |
| Serum Phe [ | 65.374 ± 27.519 |
| Serum | 0.654 0.292 |
| Serum | 0.2 0.4 |
| Serum | 0.2 0.4 |
| Serum | 0.3 0.5 |
| Serum | 0.3 0.5 |
| Serum ( | 0.5 0.7 |
| Serum ( | 0.6 1.1 |
| Urinary | 25.394 44.402 |
| Urinary | 123 (351) |
| Urinary | 194 (661) |
| Urinary | 4 (17) |
| Urinary | 9 (39) |
| Urinary ( | 21 (85) |
| Urinary | 6.952 11.645 |
| Urinary | 29 (68) |
| Urinary | 61 (220) |
| Daily excretion of | 56.268 116.710 |
| Daily excretion of | 259 (607) |
| Daily excretion of | 304 (1786) |
| Clearance of | 0.605 1.720 |
| Clearance of | 9.011 27.413* |
| Clearance of | 17.198 105.512∗† |
| FE | 1.783 2.160 |
| FE | 25.104 54.305‡ |
| FE | 85.645 639.219‡§ |
* P < 0.001 versus clearance of p-Tyr; † P = 0.019 versus clearance of m-Tyr; ‡ P < 0.001 versus FEp-Tyr; § P = 0.006 vs. FEm-Tyr.
APACHE II, acute physiology and chronic health evaluation II; MODS, multiple organ dysfunction score; SAPS II, simplified acute physiology score II; DID, daily insulin dose; IGP, insulin-glucose product; FE, fractional excretion.
Data expressed as mean ± SD or median (interquartile range).
Figure 2Urinary m-Tyr/p-Tyr ratio in septic patients requiring insulin administration, according to (a) daily insulin dose or (b) insulin-glucose product. # P = 0.005 versus DID < median; ## P = 0.01 versus IGP < median. DID, daily insulin dose; IGP, insulin-glucose product.
Figure 3Correlation of urinary m-Tyr concentration with (a) DID and (c) IGP. Correlation of urinary m-Tyr/p-Tyr ratio with (b) DID and (d) IGP in septic patients requiring insulin administration. DID, daily insulin dose; IGP, insulin-glucose product.
Predictors of carbohydrate metabolism parameters among septic patients, across the whole study period.
| DID | IGP* | |||
|---|---|---|---|---|
|
|
|
|
| |
| Serum Phe | −0.450 | 0.001 | −0.460 | 0.001 |
| Serum | 0.507 | <0.001 | 0.554 | <0.001 |
| Serum | — | — | 0.280 | 0.049 |
|
| ||||
| Urinary | 0.381 | 0.007 | 0.382 | 0.007 |
| Urinary | 0.359 | 0.011 | 0.351 | 0.013 |
| Urinary | 0.322 | 0.023 | 0.308 | 0.030 |
| Urinary ( | 0.389 | 0.006 | 0.376 | 0.008 |
Model: body weight, hsCRP, PCT, daily hydrocortisone dose, daily dobutamine dose, and the actual amino acid parameter.
DID, daily insulin dose; IGP, insulin-glucose product.
*Calculated by average daily glucose level (mmol/L) multiplied by daily insulin dose (U).
Method: stepwise.